Top 3 drug approvals February 2023: AKEEGA^®, ORSERDU™ and Opdivo^®

The month of February have seen drug approvals across the USA and Europe as NICE, the EMA and US FDA approved drugs for breast, lung and prostate cancer. Read our round-up below to keep up to date with the latest industry developments. AKEEGA ® Approved: 24 February 2023 Approving body: EMA Indication: Metastatic castration-resistant prostate cancer Although not a full approval, Janssen (Beerse, Belgium) did receive positive CHMP opinion from the EMA for AKEEGA® (niraparib and abiraterone acetate (AA) dual action tablet) plus prednisone (P) or prednisolone) in untreated metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations for adult patients...